Abstract
Objectives: Conventional imaging modalities like CT, MRI, ultrasound, and angiograph.y have provided invaluable anatomic information in the diagnosis and follow-up of hepatocellular carcinoma. Sensitivity and specificity of PET in imaging hepatocellular carcinoma are varied, ranging from 43% to 100%. The lower values are attributed to tumor lesions less than 1 cm. Despite the published data on PET and its role in post-therapy disease monitoring, there is no available data on its usefulness following trans-arterial rhenium-188 conjugated lipiodol therapy. This study is part of a Phase II study which seeks to evaluate the therapeutic potential of trans-arterial rhenium-188 conjugated lipiodol in patients with inoperable hepatocellular carcinoma (Project leader: Dr. Samuel Ang). The study aims to determine and characterize the metabolic activity of 18F-FDG in the liver of patients with hepatocellular carcinoma and to determine whether 18F-FDG is useful in the follow-up of hepatocellular carcinoma treated with rhenium-188 conjugated lipiodol. Methods: Patients who meet the inclusion criteria for the Phase II study of trans-arterial rhenium-188 conjugated lipiodol in patients with inoperable hepatoceliular carcinoma will be included in the study. Patients will undergo a FDG -PET scan of the liver within a week before trans-arterial rhenium therapy and at 1, 3 and 6
More>>
Santiago, J F.Y.;
Lim, E A;
[1]
Ang, S;
[2]
Gopez-Cervantes, J
[3]
- PET Center, St Lukes Medical Center, Manila (Philippines)
- Division of Surgical Oncology (Philippines)
- Center for Liver Diseases (Philippines)
Citation Formats
Santiago, J F.Y., Lim, E A, Ang, S, and Gopez-Cervantes, J.
Positron emission tomography (PET) using 18F-FDG (2-[18F]flouro-2-deoxy-d-glucose) to evaluate patients with inoperable hepatocellular carcinoma treated with trans-arterial rhenium 188-conjugated lipiodol therapy (work in progress).
China: N. p.,
2004.
Web.
Santiago, J F.Y., Lim, E A, Ang, S, & Gopez-Cervantes, J.
Positron emission tomography (PET) using 18F-FDG (2-[18F]flouro-2-deoxy-d-glucose) to evaluate patients with inoperable hepatocellular carcinoma treated with trans-arterial rhenium 188-conjugated lipiodol therapy (work in progress).
China.
Santiago, J F.Y., Lim, E A, Ang, S, and Gopez-Cervantes, J.
2004.
"Positron emission tomography (PET) using 18F-FDG (2-[18F]flouro-2-deoxy-d-glucose) to evaluate patients with inoperable hepatocellular carcinoma treated with trans-arterial rhenium 188-conjugated lipiodol therapy (work in progress)."
China.
@misc{etde_22083867,
title = {Positron emission tomography (PET) using 18F-FDG (2-[18F]flouro-2-deoxy-d-glucose) to evaluate patients with inoperable hepatocellular carcinoma treated with trans-arterial rhenium 188-conjugated lipiodol therapy (work in progress)}
author = {Santiago, J F.Y., Lim, E A, Ang, S, and Gopez-Cervantes, J}
abstractNote = {Objectives: Conventional imaging modalities like CT, MRI, ultrasound, and angiograph.y have provided invaluable anatomic information in the diagnosis and follow-up of hepatocellular carcinoma. Sensitivity and specificity of PET in imaging hepatocellular carcinoma are varied, ranging from 43% to 100%. The lower values are attributed to tumor lesions less than 1 cm. Despite the published data on PET and its role in post-therapy disease monitoring, there is no available data on its usefulness following trans-arterial rhenium-188 conjugated lipiodol therapy. This study is part of a Phase II study which seeks to evaluate the therapeutic potential of trans-arterial rhenium-188 conjugated lipiodol in patients with inoperable hepatocellular carcinoma (Project leader: Dr. Samuel Ang). The study aims to determine and characterize the metabolic activity of 18F-FDG in the liver of patients with hepatocellular carcinoma and to determine whether 18F-FDG is useful in the follow-up of hepatocellular carcinoma treated with rhenium-188 conjugated lipiodol. Methods: Patients who meet the inclusion criteria for the Phase II study of trans-arterial rhenium-188 conjugated lipiodol in patients with inoperable hepatoceliular carcinoma will be included in the study. Patients will undergo a FDG -PET scan of the liver within a week before trans-arterial rhenium therapy and at 1, 3 and 6 months after therapy and within a week of a follow-up CT scan. Results: Five patients (age range 43-72) with hepatocellular CA underwent trans-arterial rhenium-188 conjugated lipiodol treatment 4 out of the 5 patients had large hypermetabolic masses corresponding to the mass identified in the CT/MRI. The patient whose PET scan did not identify a lesion had no histopathological confirmation of hepatocellular CA but was included in the study due to the presence of a mass in the CT scan and elevated AFP. Three patients had undergone post therapy PET scans, two of which showed evidence of progressive disease. Follow up CT scans in these 3 patients was consistent with the PET findings in two patients. For one patient, CT scan showed decrease in size while PET showed increase in size and metabolic activity. Conclusions: These small series of inoperable hepatocellular cancer showed that FDG localized in the lesions more intensely than the rest of the liver parenchyma enabling identification and possible follow-up monitoring for response to therapy. More patients have to be enrolled in the study and longer follow-up is needed in order to fully realize whether FDG-PET scans correlate better with the clinical picture and prognosis compared to conventional diagnostic imaging and laboratory tests. (authors)}
place = {China}
year = {2004}
month = {Jul}
}
title = {Positron emission tomography (PET) using 18F-FDG (2-[18F]flouro-2-deoxy-d-glucose) to evaluate patients with inoperable hepatocellular carcinoma treated with trans-arterial rhenium 188-conjugated lipiodol therapy (work in progress)}
author = {Santiago, J F.Y., Lim, E A, Ang, S, and Gopez-Cervantes, J}
abstractNote = {Objectives: Conventional imaging modalities like CT, MRI, ultrasound, and angiograph.y have provided invaluable anatomic information in the diagnosis and follow-up of hepatocellular carcinoma. Sensitivity and specificity of PET in imaging hepatocellular carcinoma are varied, ranging from 43% to 100%. The lower values are attributed to tumor lesions less than 1 cm. Despite the published data on PET and its role in post-therapy disease monitoring, there is no available data on its usefulness following trans-arterial rhenium-188 conjugated lipiodol therapy. This study is part of a Phase II study which seeks to evaluate the therapeutic potential of trans-arterial rhenium-188 conjugated lipiodol in patients with inoperable hepatocellular carcinoma (Project leader: Dr. Samuel Ang). The study aims to determine and characterize the metabolic activity of 18F-FDG in the liver of patients with hepatocellular carcinoma and to determine whether 18F-FDG is useful in the follow-up of hepatocellular carcinoma treated with rhenium-188 conjugated lipiodol. Methods: Patients who meet the inclusion criteria for the Phase II study of trans-arterial rhenium-188 conjugated lipiodol in patients with inoperable hepatoceliular carcinoma will be included in the study. Patients will undergo a FDG -PET scan of the liver within a week before trans-arterial rhenium therapy and at 1, 3 and 6 months after therapy and within a week of a follow-up CT scan. Results: Five patients (age range 43-72) with hepatocellular CA underwent trans-arterial rhenium-188 conjugated lipiodol treatment 4 out of the 5 patients had large hypermetabolic masses corresponding to the mass identified in the CT/MRI. The patient whose PET scan did not identify a lesion had no histopathological confirmation of hepatocellular CA but was included in the study due to the presence of a mass in the CT scan and elevated AFP. Three patients had undergone post therapy PET scans, two of which showed evidence of progressive disease. Follow up CT scans in these 3 patients was consistent with the PET findings in two patients. For one patient, CT scan showed decrease in size while PET showed increase in size and metabolic activity. Conclusions: These small series of inoperable hepatocellular cancer showed that FDG localized in the lesions more intensely than the rest of the liver parenchyma enabling identification and possible follow-up monitoring for response to therapy. More patients have to be enrolled in the study and longer follow-up is needed in order to fully realize whether FDG-PET scans correlate better with the clinical picture and prognosis compared to conventional diagnostic imaging and laboratory tests. (authors)}
place = {China}
year = {2004}
month = {Jul}
}